With the aim of comparing the therapeutic efficacy, tolerability and toxicity of meglumine
antimoniate, aminosidine sulphate and pentamidine isethionate, a field study was …

We retrospectively analyzed a series of 151 cases of cutaneous leishmaniasis treated
between 1967 and 1982. One-hundred-and-thirty-nine (92%) patients presented with active …

We conducted a quasi-experimental study to compare the response to meglumine
antimoniate in patients with localized cutaneous leishmaniasis from two endemic areas of …

Seventy-nine patients with cutaneous leishmaniasis were included in this study. The
experimental group (n= 38) was treated with pentamidine isothionate in a dose of …

Efficacy and safety of meglumine antimoniate and sodium stibogluconate BP88R were
compared in cutaneous leishmaniasis treatment in Corte de Pedra, Bahia, an endemic area …

Introduction: Visceral leishmaniasis is an endemic protozoan found in Brazil. It is
characterized by fever, pallor, hepatosplenomegaly, lymphadenopathy, and progressive …

Fundamentals: American tegumentary leishmaniasis (ATL) treatment remains a challenge,
since most available drugs are injectable and only a small number of comparative …

Despite more than half a century of use in leishmaniasis, antimony therapy still presents
serious problems concerning dosage and toxicity. Low and high doses have been shown to …

Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to
Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine …

The leishmanicidal activity of four batches of meglumine antimoniate, produced in
Farmanguinhos-Fiocruz, Brazil (TAMs), was assessed and compared to Glucantime® …